Anticocaine catalytic antibodies have no affinity for RTI compounds: Implications for treatment

  title={Anticocaine catalytic antibodies have no affinity for RTI compounds: Implications for treatment},
  author={Michael J. Kuhar and F. Ivy Carroll and Narine Bharat and Donald W. Landry},
Potential medications for cocaine abusers include: anticocaine catalytic antibodies, which could serve as circulating peripheral blockers of cocaine that prevents its action in the brain; and 3‐phenyltropane cocaine analogs, which could serve as potent, selective, and long‐lasting substitutes that reduce drug‐seeking. In order to evaluate the compatibility of these agents, we measured if a catalytic antibody would bind and interact with some cocaine analogs. Anticocaine catalytic antibody 15A10… 
Anti-cocaine vaccines: antibody protection against relapse
  • K. Kantak
  • Biology
    Expert opinion on pharmacotherapy
  • 2003
If an anti-cocaine vaccine is to be clinically useful, it must induce a sufficient level of antibody in the blood to prevent easy surmountability of protection by continued cocaine use and should be compatible with other treatment medications that may be simultaneously administered.
Vaccines Against Drugs of Abuse
Vaccines against drugs of abuse are likely to work best with individuals who are highly motivated to quit using drugs altogether and as part of a comprehensive treatment programme, and the medical treatment of drug abuse will not be radically different from treatment of other chronic diseases.
Production d'anticorps monoclonaux dirigés contre la cocai͏̈ne, la méthamphétamine et leurs dérivés pour utilisation en clinique humaine
Le nombre d'intoxications aigues a la cocaine ou a la methamphetamine est en constante augmentation. Parallelement, aucune medication specifique capable de neutraliser les effets neurotoxiques de ces


Natural and artificial enzymes against cocaine. I. Monoclonal antibody 15A10 and the reinforcing effects of cocaine in rats.
The hypothesis that administration of the anticocaine catalytic monoclonal antibody mAb 15A10 would dose and time dependently reduce behavior maintained by a range of doses of i.v. cocaine was evaluated, extending previous work indicating that pharmacokinetic approaches may be of worth in the search for clinically effective cocaine antagonists.
A catalytic antibody against cocaine prevents cocaine's reinforcing and toxic effects in rats.
  • B. Mets, G. Winger, D. Landry
  • Biology, Psychology
    Proceedings of the National Academy of Sciences of the United States of America
  • 1998
Cocaine addiction and overdose have long defied specific treatment. To provide a new approach, the high-activity catalytic antibody mAb 15A10 was elicited using a transition-state analog for the
Suppression of psychoactive effects of cocaine by active immunization
It is reported here that active immunization with a new, stable cocaine conjugate suppressed locomotor activity and stereotyped behaviour in rats induced by cocaine but not by amphetamine, and suggest that immunopharmacotherapy may be a promising means by which to explore new treatments for cocaine abuse.
Development of a therapeutic vaccine for the treatment of cocaine addiction.
  • B. Fox
  • Biology, Psychology
    Drug and alcohol dependence
  • 1997
Anti-Cocaine Catalytic Antibodies: A Synthetic Approach to Improved Antibody Diversity
This work has reported the first such artificial enzymes to degrade cocaine, and it is proposed that these enzymes may be useful for drug overdose and addiction treatment.
Comparative behavioral pharmacology of cocaine and the selective dopamine uptake inhibitor RTI-113 in the squirrel monkey.
The results indicate that the behavioral pharmacology of RTI-113 is similar to that of cocaine, further implicating a prominent role for dopamine uptake inhibition in the behavioral effects of cocaine.